Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-[4-(aminosulfonyl)phenyl]-2-mercaptobenzamide is an experimental small molecule belonging to the benzanilide class, with a molecular formula of C13H12N2O3S2 and a molecular weight of approximately 308.4 g/mol[1][2]. It acts as an inhibitor of several carbonic anhydrase isoforms, specifically carbonic anhydrase 1, 2, and 9[2][3]. Carbonic anhydrases are zinc-containing enzymes involved in the reversible hydration of carbon dioxide; their inhibition can affect pH regulation and fluid balance in tissues. This compound has been investigated for its potential pharmacological actions but is not approved for any indication. Some sources also mention possible antimicrobial and antioxidant properties[10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on N-[4-(aminosulfonyl)phenyl]-2-mercaptobenzamide.